← Back to screener

Scinai Immunotherapeutics Ltd. SCNI

Rank #1253 · Nasdaq · $6.5B market cap
Audited by KOST FORER GABBAY & KASIERER, no going-concern flag in the latest filing.
Score
51.2
P/E
-797.3
P/B
-435.06
ROE
54.6%
Op. Margin
–%
Debt Ratio
-313%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -797.3x, P/B -435.06x. Ranks in the top 81% of the universe.

Profitability ★★★★★
Excellent

ROE 54.6%. Ranks in the top 7% of the universe.

Safety ★★★★★
Excellent

Debt ratio -313%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2022–$-0.0B$-0.0B$-0.0B–-313

← See the full screener